0001171843-19-003295.txt : 20190513 0001171843-19-003295.hdr.sgml : 20190513 20190513120222 ACCESSION NUMBER: 0001171843-19-003295 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190513 DATE AS OF CHANGE: 20190513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Capstone Therapeutics Corp. CENTRAL INDEX KEY: 0000887151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 860585310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21214 FILM NUMBER: 19817477 BUSINESS ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 BUSINESS PHONE: 6022865520 MAIL ADDRESS: STREET 1: 1275 WEST WASHINGTON STREET STREET 2: SUITE 101 CITY: TEMPE STATE: AZ ZIP: 85281 FORMER COMPANY: FORMER CONFORMED NAME: ORTHOLOGIC CORP DATE OF NAME CHANGE: 19940211 10-Q 1 f10q_051019.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

[ X ]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

March 31, 2019

[ ]

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File Number: 0-21214

CAPSTONE THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Delaware	86-0585310
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1275 W. Washington Street, Suite 104, Tempe, Arizona	85281
(Address of principal executive offices)	(Zip Code)

(602) 286-5520

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days (See https://www.sec.gov or Capstonethx.com).
☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

54,385,411 shares of common stock outstanding as of May 1, 2019

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CAPS	OTCQB

TABLE OF CONTENTS

Forward Looking Statements			4

Part I – Financial Information			5

	Item 1.	Financial Statements	5

		Condensed Consolidated Balance Sheets	5

		Condensed Consolidated Statements of Operations	6

		Condensed Consolidated Statements of Cash Flows	7

Notes to Unaudited Condensed Consolidated Financial Statements			8

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

	Item 4.	Controls and Procedures	23

	Disclosure Controls and Procedures		23

Part II – Other Information			23

	Item 1.	Legal Proceedings	23

	Item 6.	Exhibits	23

EXHIBIT 10.1

EXHIBIT 101

Forward Looking Statements

We may from time to time make written or oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to stockholders. The safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 protects companies from liability for their forward looking statements if they comply with the requirements of that Act. This Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2018, and contains forward-looking statements made pursuant to that safe harbor. These forward-looking statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could materially affect actual results, levels of activity, performance or achievements. Factors that may cause actual results to differ materially from current expectations, which we describe in more detail in this section titled “Risks,” include, but are not limited to:

failure of the Company, or its joint venture, LipimetiX Development, Inc., to obtain additional funds to continue operations;
the impact of the terms or conditions of agreements associated with funds obtained to fund operations;
failure to obtain additional funds required to complete clinical trials and supporting research and production efforts necessary to obtain FDA or comparable foreign agencies approval for product candidates or secure development agreements with pharmaceutical manufacturers;
the impact of using a virtual operating model;
unfavorable results of product candidate development efforts;
unfavorable results of pre-clinical or clinical testing;
delays in obtaining, or failure to obtain FDA or comparable foreign agencies approvals;
increased regulation by the FDA or comparable foreign agencies;
the introduction of competitive products;
impairment of license, patent or other proprietary rights;
the impact of present and future joint venture, collaborative or partnering agreements or the lack thereof;
failure of the Company’s common stock to continue to be listed at the OTCQB stock market; and
failure to successfully implement our drug development strategy for AEM-28 and its analogs.

If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected. Any forward-looking statement you read in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, business strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

PART I – Financial Information

Item 1. Financial Statements

CAPSTONE THERAPEUTICS CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

March 31, December 31,

2019 2018

(Unaudited)

ASSETS

Current assets

Cash $ 1,092 $ 1,341

Other current assets 129 97

Total current assets 1,221 1,438

Patent license rights, net - 39

Total assets $ 1,221 $ 1,477

LIABILITIES AND EQUITY

Current liabilities

Accounts payable $ 630 $ 245

Other accrued liabilities 102 1

Total current liabilities 732 246

Secured debt and accrued interest, net of unamortized issuance costs 2,584 2,475

Equity

Capstone Therapeutics Corp. Stockholders' Equity

Common Stock$.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018 27 27

Additional paid-in capital 190,487 190,483

Accumulated deficit (192,609 ) (191,754 )

Total Capstone Therapeutics Corp. stockholders' equity (deficit) (2,095 ) (1,244 )

Noncontrolling interest - -

Total equity (2,095 ) (1,244 )

Total liabilities and equity $ 1,221 $ 1,477

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

Three months ended March 31,

2019 2018

SUBLICENSE REVENUE $ -   $ -

OPERATING EXPENSES:

Sublicense transaction costs -   -

General and administrative 188 229

Research and development 601 301

Total operating expenses 789 530

Income (loss) after operating expenses (789 ) (530 )

Interest and other income (expense), net (63 ) (60 )

Income(loss) from operations before taxes (852 ) (590 )

Income tax benefit (expense) (3 ) 3

NET INCOME (LOSS) (855 ) (587 )

Less: Net Income (Loss) attributable to the noncontrolling interest -   -

Net Income (Loss) attributable to Capstone

Therapeutics Corp. stockholders $ (855 ) $ (587 )

Per Share Information:

Net Income (Loss), basic and diluted, attributable to

Capstone Therapeutic Corp. stockholders $ (0.02 ) $ (0.01 )

Basic and diluted shares outstanding 54,385 54,385

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS Corp.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

	Three months ended March 31,
	2019			2018

OPERATING ACTIVITIES
Net loss	$	(855	)	$	(587	)
Non cash items:
Amortization		39			39
Non-cash interest expense		59			59
Non-cash stock based interest expense		4			2
Change in other operating items:
Other current assets		(5	)		10
Accounts payable		385			6
Other accrued liabilities		74			1
Cash flows used in operating activities		(299	)		(470	)
INVESTING ACTIVITIES
Cash flows provided by investing activities		-			-
FINANCING ACTIVITIES
Secured Debt funding		50			-
Cash flows provided by financing activities		50			-
NET DECREASE IN CASH		(249	)		(470	)
CASH, BEGINNING OF PERIOD		1,341			1,275
CASH, END OF PERIOD	$	1,092		$	805

See notes to unaudited condensed consolidated financial statements

CAPSTONE THERAPEUTICS CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2019

Note A. OVERVIEW OF BUSINESS

Description of the Business

Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.

Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.

The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.

Company History

Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.

In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)

In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.

OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.

In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).

Basis of presentation, Going Concern, and Management’s Plans. The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity’s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.

In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.

Use of estimates. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.

Our significant estimates include accounting for stock-based compensation.

Legal and Other Contingencies. The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.

Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.

Joint Venture Accounting. The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.

Cash. Cash consists of balances held in commercial bank accounts.

Accounts Payable. Accounts payable includes officer compensation of $158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company’s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.

Stockholders’ Equity. During the 1^st quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1^st quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 606”) No. 2014-09 “Revenue from Contracts from Customers”. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Upfront License Fees: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Recent Accounting Pronouncements

Leases. In February 2016 the FASB issued ASU 2016-02 Leases (Topic 842) and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1^st quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.

Cooperation Agreement. In May 2018 the Company’s joint venture (“JV”) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (“ANJI”) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the “Sub-License”) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses – Research & Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities – Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000, respectively, and has been shown net. In the 1^st quarter of 2019 the Company charged costs totaling $401,000 to research and development expense related to its activities under the Cooperation Agreement.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company’s financial statements at March 31, 2019 or December 31, 2018.

Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining $3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company’s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development, Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company’s ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company’s ownership would change to 69.75%. The JV 2016 Equity Incentive Plan has 83,480 shares of the JV’s common stock available to grant, of which, at December 31, 2018, options to purchase JV common stock shares totaling 81,479 have been granted and are fully vested. All options were granted with an exercise price of $1.07, vested 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company’s fully diluted ownership (on an as-converted basis) would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase 14,126 shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company’s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately 64.31%.

LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related costs and legal expenses).

On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV’s common stock at the election of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with a ten-year term.

As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000.

Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal “as-converted” share basis with common stock holders. The Series B Preferred Stock has “as-converted” voting rights and other terms standard to a security of this nature.

The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.

Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an “as -converted” basis) stockholders.

The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2019, accounting fees of $400,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint venture’s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and expensed in the first quarter of 2018. In the 1^st quarter of 2019 a Management Fee of $50,000 was charged to expense and paid in the second quarter of 2019..

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667	)
Cash paid at formation	$	378

Patent license rights were recorded at their estimated fair value and were amortized on a straight-line basis over the key patent life of eighty months.

The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company’s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of December 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. The due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company’s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2019, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $140,000, was $1,740,000.

The joint venture incurred net operating income (expenses), prior to the elimination of intercompany transactions, of ($684,000) in 2019 and ($10,282,000) for the period from August 3, 2012 (inception) to March 31, 2019, of which ($684,000), and ($8,670,000), respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.

Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2019, losses totaling $667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2019, the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling interests.

Note C Australian Refundable Research & Development Credit

In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At December 31, 2018, expected refundable research and development tax credit of AUD$4,000, is included in Other current assets in the Condensed Consolidated Balance Sheets. The expected refundable research and development tax credits for the three-month periods ended March 31, 2019 and 2018 were AUD$0 and AUD$4,000, respectively.

Note D SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the “Agreement”) with BP Peptides, LLC (“Brookstone"). The net proceeds have been used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes totaling $1,000,000, plus $79,000 in accrued interest.

Pursuant to the Agreement, Brookstone funded an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500 was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company’s Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company’s Common Stock, representing approximately 34.1% of outstanding shares of the Company’s Common Stock at March 31, 2019.

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the “Amendment”) with Brookstone. Interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt’s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company’s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2019, 2,926,302 shares are fully vested and exercisable.

The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $4,000 and $2,000 in 1^st quarter of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000. Any additional amounts advanced will be added to the current Loan and subject to the same terms and conditions. At Brookstone’s sole discretion, the Maximum Amount may be increased to an amount not to exceed $700,000. The Company borrowed $50,000 in March 2019 against the Maximum Amount of $500,000.

Transaction costs of $287,000 have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. Additional transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2019 transaction costs of $157,000 has been amortized, and $23,000 in the 1^st quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt of $36,000 in 1^st quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2019			December 31, 2018

Secured Debt	$	2,477		$	2,427
Transaction costs		(299	)		(299	)
	$	2,178		$	2,128
Amortization		157			134
	$	2,335		$	2,262
Accrued interest		249			213
	$	2,584		$	2,475

The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the “Rights Agent”) entered into Tax Benefit Preservation Plan Agreement (the “Plan”), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017. The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring “beneficial ownership” (as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an “Acquiring Person”), in an effort to protect against a possible limitation on the Company’s ability to use its net operating loss carryforwards. The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone’s acquisition of 5,041,197 shares of the Company’s Common Stock from Biotechnology Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.

Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the “Sub-License”) with Anji Pharmaceuticals Inc. (“ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the revenue totaled $254,000 and consisted of a $100,000 payment to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement, a $100,000 advisory fee and $54,000 in legal fees. As described in Note B above, at March 31, 2019, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue recorded for the $2,000,000 payment reduced the amount of JV net losses previously allocated to the Company.

A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (‘SEC”) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2015.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following is management’s discussion of significant events in the three-month period ended March 31, 2019 and factors that affected our interim financial condition and results of operations. This should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2018.

Description of the Business

On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28 or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Critical Accounting Policies

Our critical accounting policies are those that affect or could affect our financial statements materially and involve a significant level of judgment by management. The accounting policies and related risks described in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 22, 2019, for the year ended December 31, 2018 are those that depend most heavily on these judgments and estimates. As of March 31, 2019, there have been no material changes to any of the critical accounting policies contained in our Annual Report for the year ended December 31, 2018.

Results of Operations Comparing Three-Month Period Ended March 31, 2018 to the Corresponding Period in 2017.

Sublicense Revenue: As described in Note 12 to the Financial Statements included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2019, the JV entered into a License Agreement (the “Sub-License”) with Anji Pharmaceuticals Inc. (“ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the sublicense totaled $254,000 and were separately stated on the Consolidated Statement of Operations included in the Financial Statements included in the Annual Report on Form 10-K. There was no sublicense activity in the first quarter of 2019 or 2018.

General and Administrative (“G&A”) Expenses: G&A expenses related to our ongoing operations were $188,000 in the first quarter of 2019 compared to $229,000 in the first quarter of 2018. Administration expenses were higher in the 1^st quarter of 2018 than 2019 primarily due higher JV patent legal fees in 2018.

Research and Development Expenses: Research and development expenses were $601,000 for the first quarter of 2019 compared to $301,000 for the first quarter of 2018. Our research and development expenses increased due to the availability of funds from the ANJI sublicense income received in 2018, discussed above, but continues to reflect reduced spending as our development activities of AEM-28 and its analogs were limited, as we attempt to obtain additional funding.

Interest and other income (expense), net: Interest and other income (expense), net was ($63,000) for 2019 compared to ($60,000) for 2018. The expense is interest recorded on the Secured Debt and on the issuance of Warrants.

Net Loss attributable to Capstone Therapeutics stockholders: We incurred a net loss in the first quarter of 2019 of $.9 million compared to a net loss of $.6 million in the first quarter of 2018. Net losses were comparable between periods after considering the above comments. Our operations and the development activities of AEM-28 and its analogs were limited, as we attempt to obtain additional funding.

Liquidity and Capital Resources

With the sale of our Bone Device Business in November 2003, we sold all of our revenue producing operations. Since that time, we have primarily relied on our cash and investments to finance all our operations, the focus of which has been research and development of our product candidates.

On August 3, 2012, we entered into a joint venture, to develop Apo E mimetic peptide AEM-28 and its analogs. We contributed $6.0 million and through December 31, 2018 we have loaned an additional $1,740,000 (including deferred interest of $140,000) to the JV. The JV raised $1,012,000 ($946,000 net of issuance costs) in the JV’s Series B-1 Preferred Stock and Warrant offering in August 2016. As described in Note D to the Financial Statements included in this Quarterly Report on Form 10-Q, the Company on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As disclosed in Note E to the Financial Statements included in Quarterly Report on Form 10-Q, on May 2, 2018, our JV entered into a License Agreement which resulted in the receipt of a $2,000,000 nonrefundable payment ($1,746,000 net of transaction costs). At March 31, 2019, we had cash of $1,092,000, of which $940,000 is held by our JV.

As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019, the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone. The 2^nd Amendment provides for additional advances to the Company up to a Maximum Amount of $500,000 to be used for Company operations. Advances made will be added to the secured debt and be subject to the terms and conditions of the Securities Purchase, Loan and Security Agreement. At Brookstone’s sole discretion, the Maximum Amount of the advances may be increased to an amount not exceeding $700,000. The Company borrowed $50,000 in March 2019 against the Maximum Amount of $500,000.

We intend to continue limiting our internal operations to a virtual operating model in 2019; however, without additional funding, we will also limit the development activities of AEM-28 and its analogs. Lack of additional funding for development activities of AEM-28 and its analogs could would impair our ability to continue our current operations as planned.

Funding permitting, our planned operations in 2019 consist of continuing monitoring and participating in the management of the JV’s development activities.

Our future research and development and other expenses will vary significantly from prior periods and depend on the Company’s decisions on future JV operations and obtaining additional funding.

We will require additional funds if we choose to extend the development of AEM-28 and its analogs. We cannot currently predict the amount of funds that will be required if we choose to extend the development activities of AEM-28 and its analogs and to continue operations. In any event, to complete the clinical trials and supporting research and production efforts necessary to obtain FDA or comparable foreign agencies’ approval for product candidates would require us to obtain additional capital. New sources of funds, including raising capital through the sales of our debt or equity securities, joint venture or other forms of joint development arrangements, sales of development rights, or licensing agreements, may not be available or may only be available on terms that would have a material adverse impact on our existing stockholders’ interests.

The Company has a secured loan of $2,477,500, due October 15, 2020, from BP Peptides, LLC, an entity that at March 31, 2019 owns approximately 34.1% of the Company’s common stock. Interest on the secured loan, at a rate of 6% per annum, is payable on the maturity date of the secured loan.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial and accounting officer, has reviewed and evaluated our disclosure controls and procedures (as defined in the Securities Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 10-Q. Based on that evaluation, our management, including our principal executive officer and principal financial and accounting officer, has concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings

None

Item 6. Exhibits

See the Exhibit Index following this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CAPSTONE THERAPEUTICS CORP.
(Registrant)

Signature	Title	Date

/s/ John M. Holliman, III	Chairman and Chief Executive Officer	May 13, 2019
John M. Holliman, III	(Principal Executive Officer)


/s/ Les M. Taeger	Senior Vice President and Chief	May 13, 2019
Les M. Taeger	Financial Officer
	(Principal Financial and Accounting Officer)

Capstone Therapeutics Corp.

(the “Company”)

Exhibit Index to Quarterly Report on Form 10-Q

For the Quarterly Period Ended March 31, 2019

No.	Description	Incorporated by Reference To:	Filed Herewith
10.1	Second Amendment to Securities Purchase, Loan and Security Agreement dated March 15, 2019	Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on March 15, 2019
10.2	Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-205160 for Capstone Therapeutics Corp. 2015 Equity Incentive Plan.	Form S-8 POS filed with the SEC on March 21, 2019
10.3	Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-196828 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.	Form S-8 POS filed with the SEC on March 21, 2019
10.4	Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-159238 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.	Form S-8 POS filed with the SEC on March 21, 2019
10.5	Post Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-134980 for Capstone Therapeutics Corp. 2005 Equity Incentive Plan.	Form S-8 POS filed with the SEC on March 21, 2019
31.1	Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.		X
31.2	Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as amended.		X
32	Certification of Principal Executive Officer and Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350.*
101	The following financial information from our Quarterly Report on Form 10-Q for the first quarter of fiscal year 2019, filed with the SEC on May 13, 2019 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018, (ii) the Condensed Consolidated Statements of Operations for the three months ended March 31, 2019 and 2018 (iii) the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018, and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.		X

	* Furnished herewith

EX-31.1 2 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, John M. Holliman, III certify that:

I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2019

By: /s/ John M. Holliman, III

John M. Holliman, III
Chairman and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Les M. Taeger, certify that:

I have reviewed this quarterly report on Form 10-Q of Capstone Therapeutics Corp.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 13, 2019

By: /s/ Les M. Taeger

Les M. Taeger
Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32 4 exh_32.htm EXHIBIT 32

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Capstone Therapeutics Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of John M. Holliman, III, Executive Chairman and Principal Executive Officer of the Company, and Les M. Taeger, Senior Vice President and Chief Financial Officer, and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 13, 2019

/s/ John M. Holliman, III

John M. Holliman, III

Chairman and Chief Executive Officer

(Principal Executive Officer)

/s/ Les M. Taeger

Les M. Taeger

Senior Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-101.INS 5 caps-20190331.xml XBRL INSTANCE FILE 0000887151 2019-01-01 2019-03-31 0000887151 2019-03-31 0000887151 2018-12-31 0000887151 2018-01-01 2018-03-31 0000887151 2019-05-01 0000887151 2015-12-01 2015-12-11 0000887151 2012-08-03 0000887151 2012-08-01 2012-08-03 0000887151 2012-08-02 2018-12-31 0000887151 2017-08-01 2017-08-11 0000887151 2016-03-01 2016-03-31 0000887151 2016-08-25 0000887151 2017-08-31 0000887151 2017-10-01 2017-10-27 0000887151 2018-01-01 2018-12-31 0000887151 2018-04-01 2018-06-30 0000887151 2019-03-01 2019-03-15 0000887151 2017-12-31 0000887151 2018-03-31 0000887151 caps:LipimetixMember 2019-01-01 2019-03-31 0000887151 caps:LipimetixAustraliaPtyLtdMember 2019-01-01 2019-03-31 0000887151 caps:InterestAndOtherExpensesMember 2019-01-01 2019-03-31 0000887151 caps:BrookstoneMember 2019-01-01 2019-03-31 0000887151 caps:SeriesB2PreferredStockMember 2019-01-01 2019-03-31 0000887151 caps:SeriesB1PreferredStockMember 2019-01-01 2019-03-31 0000887151 us-gaap:LicenseMember 2019-01-01 2019-03-31 0000887151 us-gaap:RoyaltyMember 2019-01-01 2019-03-31 0000887151 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000887151 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000887151 us-gaap:OtherAssetsMember 2019-01-01 2019-03-31 0000887151 us-gaap:SecuredDebtMember 2019-03-31 0000887151 caps:BrookstoneMember 2019-03-31 0000887151 caps:JointVentureMember 2019-03-31 0000887151 us-gaap:RevolvingCreditFacilityMember 2019-03-31 0000887151 caps:SeriesB1PreferredStockMember 2019-03-31 0000887151 caps:LipimetixMember 2019-03-31 0000887151 us-gaap:CommonStockMember 2019-03-31 0000887151 us-gaap:ConvertibleNotesPayableMember caps:BrookstoneMember 2019-03-31 0000887151 caps:BrookstoneMember srt:MinimumMember 2019-03-31 0000887151 us-gaap:SecuredDebtMember 2018-12-31 0000887151 caps:BrookstoneMember 2018-12-31 0000887151 caps:LipimetixAustraliaPtyLtdMember 2018-01-01 2018-03-31 0000887151 caps:InterestAndOtherExpensesMember 2018-01-01 2018-03-31 0000887151 caps:BrookstoneMember 2018-01-01 2018-03-31 0000887151 caps:SeriesB1PreferredStockMember 2018-01-01 2018-03-31 0000887151 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000887151 caps:BrookstoneMember 2017-07-01 2017-07-14 0000887151 caps:BrookstoneMember 2017-07-01 2017-07-14 0000887151 caps:SeriesB2PreferredStockMember 2017-07-01 2017-07-14 0000887151 caps:SeriesB2PreferredStockMember 2017-08-01 2017-08-31 0000887151 caps:SeriesB1PreferredStockMember 2017-08-01 2017-08-31 0000887151 caps:LipimetixMember 2012-08-01 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember srt:MaximumMember 2012-08-01 2012-08-03 0000887151 caps:ExclusiveLicenseAgreementMember srt:MinimumMember 2012-08-01 2012-08-03 0000887151 caps:SeriesB1AndB2PreferredStockMember 2012-08-01 2012-08-03 0000887151 us-gaap:SeriesAPreferredStockMember 2012-08-01 2012-08-03 0000887151 caps:VotingCommonOwnershipUnitsMember 2012-08-03 0000887151 caps:NonVotingPreferredOwnershipUnitsMember 2012-08-03 0000887151 us-gaap:PreferredStockMember 2016-03-01 2016-03-31 0000887151 srt:MinimumMember 2016-03-01 2016-03-31 0000887151 srt:MaximumMember 2016-03-01 2016-03-31 0000887151 caps:SeriesB2PreferredStockMember 2017-08-01 2017-08-11 0000887151 caps:OwnershipAsConvertedIncludingOptionsAndWarrantsMember 2017-10-01 2017-10-27 0000887151 caps:OwnershipAsConvertedMember 2018-01-01 2018-12-31 0000887151 caps:LipimetixMember 2018-01-01 2018-12-31 0000887151 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000887151 caps:SeriesB1PreferredStockMember 2016-08-01 2016-08-25 0000887151 caps:ExclusiveLicenseAgreementMember 2016-08-01 2016-08-25 0000887151 caps:ExclusiveLicenseAgreementMember srt:MinimumMember 2016-08-01 2016-08-25 0000887151 caps:ExclusiveLicenseAgreementMember srt:MaximumMember 2016-08-01 2016-08-25 0000887151 caps:SeriesB2PreferredStockMember 2016-08-01 2016-08-25 0000887151 caps:SeriesB2PreferredStockMember 2016-08-25 0000887151 caps:SeriesB1PreferredStockMember 2016-08-25 0000887151 us-gaap:NoncontrollingInterestMember 2012-08-02 2018-12-31 0000887151 caps:LipimetixAustraliaPtyLtdMember srt:MinimumMember 2014-03-01 2014-03-31 0000887151 us-gaap:ConvertibleNotesPayableMember 2017-07-14 0000887151 caps:BrookstoneMember 2017-07-14 0000887151 caps:BrookstoneMember 2017-04-01 2017-04-18 0000887151 caps:BrookstoneMember srt:MinimumMember 2017-04-18 0000887151 us-gaap:SecuredDebtMember 2019-03-15 0000887151 caps:BrookstoneMember 2019-03-15

129000

97000

1221000

1438000

39000

630000

245000

102000

1000

1221000

1477000

732000

246000

2584000

2475000

27000

190487000

190483000

-192609000

-191754000

-2095000

-1244000

-2095000

-1244000

1221000

1477000

188000

229000

601000

301000

789000

530000

-63000

-60000

-852000

-590000

3000

-3000

-855000

-587000

-855000

-587000

-0.02

-0.01

54385

3440000

2074000

287000

1000000

500000

1045000

0.435

4000

6000000

1000000

5000000

600000 5000000 0.60 0.60 0.64

-1500000

120000

3500000

1000000

15000

0.622 0.6975

83480

81479

1.07

0.50

0.6511

14126

10.70

0.6431 400000 0.40

378000

66000

94537

33088

10.70

0.03 25000 50000

500000

1000000

0.05

20000

400000

300000 50000

150000

667000

378000

1740000

140000

946000

-684000 -10282000 -8670000 684000

667000

2477000

2427000

299000

0 0

-789000

-530000

-855000

-587000

39000

59000

4000

2000

5000

-10000

385000

6000

74000

1000

-299000

-470000

50000

-249000

-470000

1341000

1275000

1092000

805000

158000

135000

114000

2178000

2128000

157000

134000

2335000 2262000

249000

213000

2584000

2475000

93458

1000000

79000

3440000

2074000

1012500

13500000

2427500

5041197

18541197

0.0499

5041197

100000 100000

54000

2000000

1092000

1341000

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-left: 0.5in; text-indent: -0.5in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note A. OVERVIEW OF BUSINESS</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.03in; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of the Business</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Current Peptide Drug Candidates.</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Apo E Mimetic Peptide Molecule – AEM-28 and its analogs</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Company History</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prior to November 2003, we developed, manufactured and marketed proprietary, technologically advanced orthopedic products designed to promote the healing of musculoskeletal bone and tissue, with particular emphasis on fracture healing and spine repair. Our product lines, which included bone growth stimulation and fracture fixation devices, are referred to as our “Bone Device Business.” In November 2003, we sold our Bone Device Business.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2004, we purchased substantially all of the assets and intellectual property of Chrysalis Biotechnology, Inc., including its exclusive worldwide license for Chrysalin, a peptide, for all medical indications. Subsequently, our efforts were focused on research and development of Chrysalin with the goal of commercializing our products in fresh fracture healing. (In March 2012, we returned all rights to the Chrysalin intellectual property and no longer have any interest in, or rights to, Chrysalin.)</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2006, we purchased certain assets and assumed certain liabilities of AzERx, Inc. Under the terms of the transaction, we acquired an exclusive license for the core intellectual property relating to AZX100, an anti-fibrotic peptide. In 2014, we terminated the License Agreement with AzTE (Licensor) for the core intellectual property relating to AZX100 and returned all interest in and rights to the AZX100 intellectual property to the Licensor.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our development activities represent a single operating segment as they shared the same product development path and utilized the same Company resources. As a result, we determined that it is appropriate to reflect our operations as one reportable segment.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">OrthoLogic Corp. commenced doing business under the trade name of Capstone Therapeutics on October 1, 2008, and we formally changed our name from OrthoLogic Corp. to Capstone Therapeutics Corp. on May 21, 2010.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In these notes, references to “we”, “our”, “us”, the “Company”, “Capstone Therapeutics”, “Capstone”, and “OrthoLogic” refer to Capstone Therapeutics Corp. References to our joint venture or “JV”, refer to LipimetiX Development, Inc. (formerly LipimetiX Development, LLC).</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of presentation, Going Concern, and Management’s Plans. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management has determined that the Company will require additional capital above its current cash and working capital balances to further develop AEM-28 and its analogs or to continue operations. Accordingly, the Company has significantly reduced its development activities. The Company’s corporate strategy is to raise funds by possibly engaging in a strategic/merger transaction or conducting a private or public offering of debt or equity securities for capital. As described in Note D below, the Company, on July 14, 2017, raised $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes, and transaction costs of $287,000. As discussed in Note B below, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity’s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, the unaudited condensed interim financial statements include all adjustments necessary for the fair presentation of our financial position, results of operations, and cash flows, and all adjustments were of a normal recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the complete fiscal year. The financial statements include the consolidated results of Capstone Therapeutics Corp. and our approximately 60% owned subsidiary, LipimetiX Development, Inc. Intercompany transactions have been eliminated.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to Securities and Exchange Commission rules and regulations, although we believe that the disclosures herein are adequate to make the information presented not misleading. These unaudited condensed financial statements should be read in conjunction with the financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. Information presented as of December 31, 2018 is derived from audited financial statements.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">  </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of estimates.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our significant estimates include accounting for stock-based compensation.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Legal and Other Contingencies</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Joint Venture Accounting. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash.</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash consists of balances held in commercial bank accounts.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Payable. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable includes officer compensation of </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company’s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders’ Equity.</div>     During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU 606”) No. 2014-09 “Revenue from Contracts from Customers”. Pursuant to ASC 606, revenue is recognized by the Company when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Upfront License Fees</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license.  For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees.  The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> In February 2016 the FASB issued ASU 2016-02 </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases (Topic 842) </div> and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cooperation Agreement.</div>  In May 2018 the Company’s joint venture (“JV”) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (“ANJI”) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the “Sub-License”) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses – Research & Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities – Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000, respectively, and has been shown net. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 the Company charged costs totaling $401,000 to research and development expense related to its activities under the Cooperation Agreement.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company’s financial statements at March 31, 2019 or December 31, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.60

6000000

93458

0 1012000 946000

946000

52000

50000

0.0005

150000000

54385411

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a Contribution Agreement with LipimetiX, LLC to form a joint venture, LipimetiX Development, LLC (“JV”), to develop Apo E mimetic molecules, including AEM-28 and its analogs. In June 2015, the JV converted from a limited liability company to a corporation, LipimetiX Development, Inc. The Company contributed $6 million, which included $1 million for 600,000 voting common ownership units (now common stock), representing 60% ownership in the JV, and $5 million for 5,000,000 non-voting preferred ownership units (now Series A Preferred Stock), which have preferential distribution rights. On March 31, 2016, the Company converted 1,500,000 shares of its preferred stock into 120,000 shares of common stock, increasing its common stock ownership from 60% to 64%. On August 11, 2017, the remaining $3,500,000 (3,500,000 shares) of Series A preferred stock became convertible, at the Company’s option, into common stock, at the lower of the Series B Preferred Stock Conversion Price, as may be adjusted for certain events, or the price of the next LipimetiX Development, Inc. financing, exceeding $1,000,000 on independently set valuation and terms. On August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000 (LipimetiX Development, Inc. incurred $15,000 in transaction costs as part of the Series B-2 Preferred Stock issuance, which was been shown as a reduction of Additional Paid in Capital on the Consolidated Statements of Changes in Equity and a cash flow provided by financing activities in the Consolidated Statements of Cash Flows at December 31, 2017). As discussed below, the JV Series B-1 and B-2 Preferred Stock issuances, because of the participating and conversion features of the preferred stock, effectively changes the Company’s ownership in the JV to 62.2%. With the Series B-1 and B-2 Preferred Stock on an as-converted basis, and the Company converting its Series A Preferred Stock to common stock, the Company’s ownership would change to 69.75%. The JV 2016 Equity Incentive Plan has 83,480 shares of the JV’s common stock available to grant, of which, at December 31, 2018, options to purchase JV common stock shares totaling 81,479 have been granted and are fully vested. All options were granted with an exercise price of $1.07, vested 50% on the date of grant and monthly thereafter in equal amounts over a twenty-four-month period and are exercisable for ten years from the date of grant. If all stock available to grant in the JV 2016 Equity Incentive Plan were granted and exercised, and the Series B-1 Preferred Stock Warrants were exercised, the Company’s fully diluted ownership (on an as-converted basis) would be approximately 65.11%. On October 27, 2017 the Board granted Mr. Holliman an option to purchase 14,126 shares of the LipimetiX Development, Inc. Series B-2 Preferred Stock it currently owns, at an exercise price of $10.70 per share, subject to adjustment and other terms consistent with the Series B-2 Preferred Stock. The option is exercisable for a five-year period from the date of grant. If exercised, this option would reduce the Company’s fully diluted ownership (on an as-converted basis including assumed exercise of other options and warrants) to approximately 64.31%.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">LipimetiX, LLC was formed by the principals of Benu BioPharma, Inc. (“Benu”) and UABRF to commercialize UABRF’s intellectual property related to Apo E mimetic molecules, including AEM-28 and analogs. Benu is currently composed of Dennis I. Goldberg, Ph.D. and Eric M. Morrel, Ph.D. LipimetiX, LLC contributed all intellectual property rights for Apo E mimetic molecules it owned and assigned its Exclusive License Agreement between The University of Alabama at Birmingham Research Foundation (“UABRF”) and LipimetiX, LLC, for the UABRF intellectual property related to Apo E mimetic molecules AEM-28 and its analogs to the JV, in return for 400,000 voting common ownership units (now common stock), representing a 40% ownership interest in the JV at formation, and $378,000 in cash (for certain initial patent-related costs and legal expenses).</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 25, 2016, LipimetiX Development, Inc. closed a Series B-1 Preferred Stock offering, raising funds of $1,012,000 ($946,000 net of issuance costs of approximately $66,000). Individual accredited investors and management participated in the financing. This initial closing of the Series B-1 Preferred Stock offering resulted in the issuance of 94,537 shares of preferred stock, convertible to an equal number of the JV’s common stock at the election of the holders and warrants to purchase an additional 33,088 shares of JV preferred stock, at an exercise price of $10.70, with a ten-year term.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Series B (B-1 and B-2) Preferred Stock is a participating preferred stock. As a participating preferred, the preferred stock will earn a 5% dividend, payable only upon the election by the JV or in liquidation. Prior to the JV common stock holders receiving distributions, the participating preferred stockholders will receive their earned dividends and payback of their original investment. Subsequently, the participating preferred will participate in future distributions on an equal “as-converted” share basis with common stock holders. The Series B Preferred Stock has “as-converted” voting rights and other terms standard to a security of this nature.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Exclusive License Agreement assigned by LipimetiX, LLC to the JV on formation of the JV, as amended, calls for payment of patent filing, maintenance and other related patent fees, as well as a royalty of 3% on Net Sales of Licensed Products during the Term of the Agreement. The Agreement terminates upon the expiration of all Valid Patent Claims within the Licensed Patents, which are currently estimated to expire between 2019 and 2035. The Agreement, as amended, also calls for annual maintenance payments of $25,000, various milestone payments of $50,000 to $500,000 and minimum royalty payments of $500,000 to $1,000,000 per year commencing on January 1 of the first calendar year following the year in which the First Commercial Sale occurs. UABRF will also be paid 5% of Non-Royalty Income received.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with entering into the Contribution Agreement and the First Amendment and Consent to Assignment of Exclusive License Agreement between LipimetiX, LLC, UABRF and the Company, the Company and LipimetiX, LLC entered into a Limited Liability Company Agreement for JV which established a Joint Development Committee (“JDC”) to manage JV development activities. Upon conversion by the JV from a limited liability company to a corporation, the parties entered into a Stockholders Agreement for the JV, and the JDC was replaced by a Board of Directors (JV Board). The JV Board is composed of three members appointed by the non-Company common stock ownership group, three members appointed by the Company and one member appointed by the Series B-1 Preferred Stockholders. Non-development JV decisions, including the issuance of new equity, incurrence of debt, entry into strategic transactions, licenses or development agreements, sales of assets and liquidation, and approval of annual budgets, will be decided by a majority vote of the common and Series B Preferred Stock (voting on an “as -converted” basis) stockholders.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV, on August 3, 2012, entered into a Management Agreement with Benu to manage JV development activities and an Accounting Services Agreement with the Company to manage JV accounting and administrative functions. The services related to these agreements have been completed. New Management and Accounting Services Agreements were entered into effective June 1, 2016. However, no Management or Accounting Services fees are due or payable except to the extent funding is available, as unanimously approved by members of the JV Board of Directors and as reflected in the approved operating budget in effect at that time. In August 2017 the Accounting Services Agreement monthly fee was increased to $20,000 and will thereafter be accrued but not payable, until certain levels of joint venture funding are obtained from non-affiliated parties. At March 31, 2019, accounting fees of $400,000 were earned but unpaid. In August 2017, a Management Fee of $300,000 was approved by the joint venture’s Board of Directors with $150,000 paid and charged to expense in the third quarter of 2017 and $150,000 paid and expensed in the first quarter of 2018. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 a Management Fee of $50,000 was charged to expense and paid in the second quarter of 2019..</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The joint venture formation was as follows ($000’s):</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0.50in;width: 50%;"><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 77.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Patent license rights</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 20.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">1,045</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(667</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash paid at formation</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">378</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Patent license rights were recorded at their estimated fair value and were amortized on a straight-line basis over the key patent life of eighty months.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. In the Company’s consolidated financial statements, joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were being allocated to the Series A preferred ownership equity (100% Company). Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016 the JV raised $1,012,000, ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 of losses were allocated to the Series B-1 Preferred Stock ownership interests. As of December 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture, with the loan due December 31, 2016. The due date of the revolving loan was extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Subsequent to June 30, 2017, interest due on the revolving loan will be accrued and payable only upon certain additional funding of the joint venture by non-affiliated parties. Until repayment, the outstanding revolving loan and interest balance is convertible, at the Company’s option, into Series B Preferred Stock at the Series B-1 conversion price. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of the unpaid loan and accrued interest balance. At March 31, 2019, the revolving loan agreement balance, including accrued interest subsequent to June 30, 2017 of $140,000, was $1,740,000.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The joint venture incurred net operating income (expenses), prior to the elimination of intercompany transactions, of ($684,000) in 2019 and ($10,282,000) for the period from August 3, 2012 (inception) to March 31, 2019, of which ($684,000), and ($8,670,000), respectively, have been recorded by the Company. The joint venture operating expenses are included in research and development expenses in the condensed consolidated statements of operations.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. Losses allocated to the common stock noncontrolling interests represent an additional potential loss for the Company as the common stock noncontrolling interests are not obligated to contribute assets to the joint venture and, depending on the ultimate outcome of the joint venture, the Company could potentially absorb all losses associated with the joint venture. From formation of the joint venture, August 3, 2012, through March 31, 2019, losses totaling $667,000 have been allocated to the common stock noncontrolling interests. If the joint venture or Company is unable to obtain additional funding, the ability of the joint venture to continue development of AEM-28 and its analogs would be impaired as would the joint venture’s ability to continue operations. If the joint venture does not continue as a going concern, at March 31, 2019, the Company would incur an additional loss of $667,000 for the joint venture losses allocated to the common stock noncontrolling interests.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1.00

1012000 946000 <div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note C </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Australian Refundable Research & Development Credit</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In March 2014, LipimetiX Development LLC, (Now LipimetiX Development, Inc. - see Note B above) formed a wholly-owned Australian subsidiary, Lipimetix Australia Pty Ltd, to conduct Phase 1a and Phase1b/2a clinical trials in Australia. Currently Australian tax regulations provide for a refundable research and development tax credit equal to 43.5% of qualified expenditures. Subsequent to the end of its Australian tax years, Lipimetix Australia Pty Ltd submits claims for a refundable research and development tax credit. At December 31, 2018, expected refundable research and development tax credit of AUD$4,000, is included in Other current assets in the Condensed Consolidated Balance Sheets.  The expected refundable research and development tax credits for the three-month periods ended March 31, 2019 and 2018 were AUD$0 and AUD$4,000, respectively.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

0.341

287000

12000

157000

23000

142000

165000

249000

213000

36000

2017-04-30

Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

1000000

10-Q false 2019-03-31 2019 Q1 Capstone Therapeutics Corp. 0000887151 --12-31 Non-accelerated Filer CAPS 54385411 false true

<div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 7, 2018, on May 2, 2018, our JV, LipimetiX Development, Inc., entered into a License Agreement (the “Sub-License”) with Anji Pharmaceuticals Inc. (“ANJI") to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). The Sub-License calls for an initial payment of $2,000,000, payment of a royalty on future Net Sales in the Territory and cash milestone payments based on future clinical/regulatory events. ANJI will perform all development activities allowed under the Sub-License in the Territory at its sole cost and expense. The JV recorded the receipt of the $2,000,000 payment as revenue in the second quarter of 2018. Transaction costs related to the revenue totaled $254,000 and consisted of a $100,000 payment to the UAB Research Foundation, as required by the UAB Research Foundation Exclusive License Agreement, a $100,000 advisory fee and $54,000 in legal fees. As described in Note B above, at March 31, 2019, JV net losses exceeded the JV capital accounts and all losses were being allocated to the Company. Revenue recorded for the $2,000,000 payment reduced the amount of JV net losses previously allocated to the Company.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A copy of the UAB Research Foundation Exclusive License Agreement was attached as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with Securities and Exchange Commission (‘SEC”) on August 10, 2012. A copy of the First Amendment and Consent to Assignment of the Exclusive License Agreement was attached as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the period ending June 30, 2012 filed with the SEC on August 10, 2012. The Second Amendment to the Exclusive License Agreement was attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 30, 2015.</div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note D </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; text-transform: uppercase; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT</div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 17, 2017, on July 14, 2017, the Company entered into a Securities Purchase, Loan and Security Agreement (the “Agreement”) with BP Peptides, LLC (“Brookstone"). The net proceeds have been used to fund our operations, infuse new capital into our joint venture, LipimetiX Development, Inc. ("JV") (As described in Note B above, in August 2017, the Company used $1,000,000 of the net proceeds to purchase 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock.), to continue its development activities, and pay off the Convertible Promissory Notes totaling $1,000,000, plus $79,000 in accrued interest.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Agreement, Brookstone funded an aggregate of $3,440,000, with net proceeds of approximately $2,074,000, after paying off the Convertible Promissory Notes and transaction costs, of which $1,012,500 was for the purchase of 13,500,000 newly issued shares of our Common Stock, and $2,427,500 was in the form of a secured loan, due October 15, 2020. On July 14, 2017 Brookstone also purchased 5,041,197 shares of the Company’s Common Stock directly from Biotechnology Value Fund affiliated entities, resulting in ownership of 18,541,197 shares of the Company’s Common Stock, representing approximately 34.1% of outstanding shares of the Company’s Common Stock at March 31, 2019.</div></div><div style="background: none; font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1, 2018, on January 30, 2018, the Company entered into the First Amendment to Securities Purchase, Loan and Security Agreement (the “Amendment”) with Brookstone. Interest on the Secured Debt was payable quarterly. The Amendment defers the payment of interest until the Secured Debt’s maturity, October 15, 2020. In consideration for the deferral, the Company issued a Warrant to Brookstone to purchase up to 6,321,930 shares of the Company’s Common Stock with an exercise price of $.075 per share. The warrant expires October 15, 2025 and provides for quarterly vesting of shares in amounts approximately equal to the amount of quarterly interest payable that would have been payable under the Agreement, converted into shares at $0.75. At March 31, 2019, 2,926,302 shares are fully vested and exercisable.</div></div><div style="background: none; font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 12pt;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Warrants was determined to be $43,000. The fair value of the Warrants will be amortized over the deferral period, January 30, 2018 to October 15, 2020, on the straight-line basis, as additional interest expense. Amortization expenses totaled $4,000 and $2,000 in 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000. Any additional amounts advanced will be added to the current Loan and subject to the same terms and conditions. At Brookstone’s sole discretion, the Maximum Amount may be increased to an amount not to exceed $700,000. The Company borrowed $50,000 in March 2019 against the Maximum Amount of $500,000.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs of $287,000 have been deferred and will be written off over the life of the secured loan, thirty-nine months from July 14, 2017 to October 20, 2020, on the straight-line basis. Additional transaction costs of $12,000 were incurred with the Amendment and will be written off over the period of the date of the Amendment, January 30, 2018, to October 15, 2020. At March 31, 2019 transaction costs of $157,000 has been amortized, and $23,000 in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt of $36,000 in 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Secured Debt activity is as follows (000’s):</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Secured Debt</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,477</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,427</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,178</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">157</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">134</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,335</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,262</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">249</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,584</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,475</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The secured loan bears interest at 6% per annum, with interest payable quarterly (now due at loan maturity) and is secured by a security interest in all of our assets. As part of the Agreement, the Company and Brookstone entered into a Registration Rights Agreement granting Brookstone certain demand and piggyback registration rights. </div><div style="background: rgb(255, 255, 255); font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.</div></div><div style="background: none; font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background: #ffffff;font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On April 18, 2017, the Company and Computershare Trust Company, N.A., as Rights Agent (the “Rights Agent”) entered into Tax Benefit Preservation Plan Agreement (the “Plan”), dated as of April 18, 2017, between the Company and the Rights Agent, as described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 19, 2017.  The Plan is intended to act as a deterrent to any person (together with all affiliates and associates of such person) acquiring “beneficial ownership” (as defined in the Plan) of 4.99% or more of the outstanding shares of Common Stock without the approval of the Board (an “Acquiring Person”), in an effort to protect against a possible limitation on the Company’s ability to use its net operating loss carryforwards.  The Board, in accordance with the Plan, granted an Exemption to Brookstone with respect to the share acquisition described above, and Brookstone’s acquisition of 5,041,197 shares of the Company’s Common Stock from Biotechnology Value Fund affiliated entities, making Brookstone an Exempt Person in respect of such transactions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">A summary of the Secured Debt activity is as follows (000’s):</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 70%;margin-left: auto;margin-right: auto;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2019</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="2" style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 74.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Secured Debt</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,477</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,427</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(299</div></div></td><td style="background: rgb(255, 255, 255); border-width: initial; border-style: none; border-color: initial; padding-bottom: initial; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,178</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,128</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">157</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">134</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,335</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,262</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accrued interest</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">249</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">213</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,584</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,475</div></div></td><td style="background: rgb(204, 238, 255); border-width: initial; border-style: none; border-color: initial; padding: 0px 0px 1.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

401000

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> In February 2016 the FASB issued ASU 2016-02 </div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases (Topic 842) </div> and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cooperation Agreement.</div>  In May 2018 the Company’s joint venture (“JV”) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (“ANJI”) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the “Sub-License”) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses – Research & Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities – Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $<div style="display:inline;">52,000</div>, respectively, and has been shown net. In the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 the Company charged costs totaling $<div style="display:inline;">401,000</div> to research and development expense related to its activities under the Cooperation Agreement.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-18 Collaborative Arrangements (Topic 808) - Clarifying the Interaction between Topic 808 and Topic 606. This ASU is effective for effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. As provided for in the ASU, the Company has elected to early adopt the ASU. The adoption of the ASU did not have a material effect on the Company’s financial statements at March 31, 2019 or December 31, 2018.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders’ Equity.</div>     During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1<div style="vertical-align: super;font-size: smaller;display:inline;">st</div> quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.</div></div><div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

4000 2000

28000

6321930

4000

2000

43000

500000 50000

2926302

0.75

0.20

0.05

0.06

2025-10-15

254000 416000 500000 <div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-left: 0.50in;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of the Business</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.5in; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Capstone Therapeutics Corp. (the “Company”, “we”, “our” or “us”) is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). In 2012, we terminated the license for Chrysalin (targeting orthopedic indications). In 2014, we terminated the license for AZX100 (targeting dermal scar reduction). Capstone no longer has any rights to or interest in Chrysalin or AZX100.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (now LipimetiX Development, Inc.), (the “JV”), to develop Apo E mimetic peptide molecule AEM-28 and its analogs. The JV has a development plan to pursue regulatory approval of AEM-28, or an analog, as treatment for Homozygous Familial Hypercholesterolemia, other hyperlipidemic indications, and acute coronary syndrome/atherosclerosis regression. The initial AEM-28 development plan extended through Phase 1a and 1b/2a clinical trials and was completed in the fourth quarter of 2014. The clinical trials had a safety primary endpoint and an efficacy endpoint targeting reduction of cholesterol and triglycerides.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In early 2014, the JV received allowance from regulatory authorities in Australia permitting the JV to proceed with the planned clinical trials. The Phase 1a clinical trial commenced in Australia in April 2014 and the Phase 1b/2a clinical trial commenced in Australia in June 2014. The clinical trials for AEM-28 were randomized, double-blinded, placebo-controlled studies to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of six escalating single doses (Phase 1a in healthy patients with elevated cholesterol) and multiple ascending doses of the three highest doses from Phase 1a (Phase 1b/2a in patients with hypercholesterolemia and healthy volunteers with elevated cholesterol and high Body Mass Index). The Phase 1a clinical trial consisted of 36 patients and the Phase 1b/2a consisted of 15 patients. Both clinical trials were completed in 2014 and the Medical Safety Committee, reviewing all safety-related aspects of the clinical trials, observed a generally acceptable safety profile. As first-in-man studies, the primary endpoint was safety; yet efficacy measurements analyzing pharmacodynamics yielded statistical significance in the pooled dataset favoring AEM-28 versus placebo in multiple lipid biomarker endpoints.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the clinical development activities of AEM-28, the JV has performed pre-clinical studies that have identified analogs of AEM-28, and new formulations, that have the potential of increased efficacy, higher human dose toleration and an extended composition of matter patent life (application filed with the U.S. Patent and Trademark Office in 2014).</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The JV and the Company do not have sufficient funding at this time to continue additional material development activities. The JV may conduct future clinical trials in Australia, the USA, and other regulatory jurisdictions if regulatory approvals, additional funding, and other conditions permit.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company, funding permitting, intends to continue limiting its internal operations to a virtual operating model while monitoring and participating in the management of JV’s development activities.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Current Peptide Drug Candidates.</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Apo E Mimetic Peptide Molecule – AEM-28 and its analogs</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Apolipoprotein E is a 299 amino acid protein that plays an important role in lipoprotein metabolism. Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 analogs are also 28 amino acid mimetics of Apo E (with an aminohexanoic acid group and a phospholipid). Both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28 and its analogs, as Apo E mimetics, have the potential to restore the ability of these atherogenic lipoproteins to be cleared from the plasma, completing the reverse cholesterol transport pathway, and thereby reducing cardiovascular risk. This is an important mechanism of action for AEM-28 and its analogs. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases. Our joint venture has an Exclusive License Agreement with the University of Alabama at Birmingham Research Foundation for a broad domain of Apo E mimetic peptides, including AEM-28 and its analogs.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.5in; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Joint Venture Accounting. </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

2000000

855000

587000

1000000

93458

0.75

700000

500000

iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares EX-101.SCH 6 caps-20190331.xsd XBRL SCHEMA FILE 1001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 1006 - Disclosure - OVERVIEW OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - OVERVIEW OF BUSINESS (Policies) link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 caps-20190331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 caps-20190331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 caps-20190331_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Trading Symbol Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Small Business Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets Other Assets, Current Other current assets Assets, Current Total current assets Finite-Lived Intangible Assets, Net Patent license rights, net Assets Total assets Cash and Cash Equivalents, at Carrying Value Cash CASH, BEGINNING OF PERIOD CASH, END OF PERIOD Liabilities and Equity [Abstract] LIABILITIES AND EQUITY Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Other accrued liabilities Liabilities, Current Total current liabilities Secured Long-term Debt, Noncurrent Secured debt and accrued interest, net of unamortized issuance costs Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Equity Stockholders' Equity Attributable to Parent [Abstract] Capstone Therapeutics Corp. Stockholders' Equity Common Stock, Value, Issued Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018 Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Total Capstone Therapeutics Corp. stockholders' equity (deficit) Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Total equity Liabilities and Equity Total liabilities and equity Balance Sheet [Parenthetical] [Abstract] Balance Sheet Parenthetical. Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Operating Expenses [Abstract] OPERATING EXPENSES: General and Administrative Expense General and administrative Research and Development Expense (Excluding Acquired in Process Cost) Research and development Operating Expenses Total operating expenses Sublicense Transaction Costs Sublicense transaction costs The amount of sublicense transaction costs recognized during the period. Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted shares outstanding Net Income (Loss) Attributable to Parent Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders Earnings Per Share, Basic and Diluted [Abstract] Per Share Information: Earnings Per Share, Basic and Diluted Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders Other Nonoperating Income (Expense) Interest and other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (loss) from operations before taxes Income Tax Expense (Benefit) Income tax benefit (expense) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest NET INCOME (LOSS) Net loss Net Income (Loss) Attributable to Noncontrolling Interest Less: Net Income (Loss) attributable to the noncontrolling interest Operating Income (Loss) Income (loss) after operating expenses Revenues SUBLICENSE REVENUE Statement of Cash Flows [Abstract] Legal Entity [Axis] Entity [Domain] Net Cash Provided by (Used in) Operating Activities [Abstract] OPERATING ACTIVITIES Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Non cash items: Amortization Amortization Other Noncash Expense Non-cash interest expense Share-based Compensation Non-cash stock based interest expense Increase (Decrease) in Operating Capital [Abstract] Change in other operating items: Increase (Decrease) in Other Current Assets Other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Other Accrued Liabilities Other accrued liabilities Net Cash Provided by (Used in) Operating Activities Cash flows used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Cash flows provided by investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities Cash flows provided by financing activities Secured Debt funding Cash and Cash Equivalents, Period Increase (Decrease) NET DECREASE IN CASH Accounting Policies [Abstract] Business Description and Accounting Policies [Text Block] Business Combinations [Abstract] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Research and Development Expense [Abstract] Refundable Research And Development Credit [Text Block] The entire disclosure for Refundable Research & Development Credit during the period. Stockholders' Equity Note [Abstract] Issuance Of Common Stock And Secured Debt Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Description Of Business [Policy Text Block] Description Of Business [Policy Text Block] Disclosure of accounting policy for description of business. Company History [Policy Text Block] Company History [Policy Text Block] Disclosure of accounting policy for company history. Basis Of Presentation and Management Plan [Policy Text Block] Basis Of Presentation and Management Plan [Policy Text Block] Disclosure of accounting policy for basis of presentation and management plan. Use of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block] Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block] Commitments and Contingencies, Policy [Policy Text Block] Commitments and Contingencies, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Accounts Payable Policy [Policy Text Block] Accounting policy for payables Stockholders' Equity, Policy [Policy Text Block] Schedule Of Joint Venture Payments [Table Text Block] Schedule Of Joint Venture Payments [Table Text Block] Tabular disclosure of payments in formation of joint venture. Schedule of Debt [Table Text Block] Accounting Policies [Table] Range [Axis] Range [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Brookstone [Member] Lipimetix [Member] Credit Facility [Axis] Credit Facility [Domain] Series B2 Preferred Stock [Member] Series B1 Preferred Stock [Member] Series B-1 Preferred Stock [Member] Accounting Policies [Line Items] Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds From Issunance Of Preferred Stock Before Adjusted Stock Issuance Costs Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs Represent that cash inflow for issuance of preferred stock before adjusted stock offering costs. Proceeds from Related Party Debt Proceeds From Related Party Debt, Net Net Proceeds from related party debt after adjustments. Stock Issued During Period, Value, Acquisitions Stock Issued During Period, Shares, Acquisitions Payments of Stock Issuance Costs Line of Credit Facility, Maximum Borrowing Capacity Accounts Payable Research and Development Expense Reimbursement of revenue Amount received for expenses incured. Equity Method Investment, Ownership Percentage Joint Venture Losses Recognition Criteria Common Ownership Equity Joint Venture Losses Recognition Criteria, Common Ownership Equity Represents the common ownership equity value, upon which the company records joint venture losses. Amortisation Of Financing Cost Of Warrants Amortisation Of Financing Cost Of Warrants Operating Lease, Right-of-Use Asset Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Accounts Payable Corporation Agreement Accounts Payable with Corporation Agreement. Additional fund for operations Additional Funding for Operations Product and Service [Axis] Product and Service [Domain] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Other Assets [Member] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Noncash or Part Noncash Acquisition, Intangible Assets Acquired Patent license rights Noncash or Part Noncash Acquisition, Other Liabilities Assumed Noncontrolling interests Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Cash paid at formation Agreement [Axis] Agreement [Domain] Exclusive License Agreement [Member] Maximum [Member] Minimum [Member] Preferred Stock [Member] Noncontrolling Interest [Member] Voting Common Ownership Units [Member] Non Voting Preferred Ownership Units [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Revolving Credit Facility [Member] Series B1 And B2 Preferred Stock [Member] Series A Preferred Stock [Member] Royalty Expense Royalty Expense Percentage Of Non Royalty Income Percentage Of Non Royalty Income It represents the percentage of non royalty income. Joint Venture Investments In Voting Common Ownership Units Joint Venture Investments In Voting Common Ownership Units (in shares) Share represents joint venture investments in voting common ownership units. Joint Venture Investments In Non Voting Preferred Ownership Units Joint Venture Investments In Non Voting Preferred Ownership Units Share represents joint venture investments in non voting preferred ownership. Joint Venture Investments Common Ownership Units Coventure Joint Venture Investments Common Ownership Units, Co-venture (in shares) Share represents joint venture investments common ownership units of co-venture. Ownership Percentage Coventure Ownership Percentage Co-venture Ownership percentage of co- venture. Percentage Of Royalty Payment Percentage Of Royalty Payment Percentage of royalty payment. Joint Venture Operating Expenses Inter Company Transactions Joint Venture, Operating Expenses, Inter Company Transactions Represents the operating expenses incurred by joint venture, in relation to inter company transactions. Joint Venture, Operating Expenses Allocated To Company Joint Venture, Operating Expenses Allocated To Company Represents the operating expenses incurred by joint venture allocated to the company. Annual Maintenance Payments Annual Maintenance Payments It represents the value of annual maintenance payments during the period. Milestone Payments Milestone Payments It represents the value of milestone payments during the period. Noncontrolling Interest, Ownership Percentage by Parent Long-term Line of Credit Conversion of Stock, Shares Converted Conversion of Stock, Shares Converted Class of Warrant or Right, Exercise Price of Warrants or Rights Management Fees Amount represents the monthly management fees for services rendered during the period. Conversion of Stock, Shares Issued Joint Venture Method Investment Ownership Percentage Percentage represents joint venture method investment ownership. Stock Issued During Period, Shares, New Issues Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage EX-101.PRE 10 caps-20190331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 01, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	Capstone Therapeutics Corp.
Entity Central Index Key	0000887151
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	CAPS
Entity Common Stock, Shares Outstanding		54,385,411
Entity Emerging Growth Company	false
Entity Small Business	true

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash	$ 1,092	$ 1,341
Other current assets	129	97
Total current assets	1,221	1,438
Patent license rights, net	0	39
Total assets	1,221	1,477
Current liabilities
Accounts payable	630	245
Other accrued liabilities	102	1
Total current liabilities	732	246
Secured debt and accrued interest, net of unamortized issuance costs	2,584	2,475
Capstone Therapeutics Corp. Stockholders' Equity
Common Stock $.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018	27	27
Additional paid-in capital	190,487	190,483
Accumulated deficit	(192,609)	(191,754)
Total Capstone Therapeutics Corp. stockholders' equity (deficit)	(2,095)	(1,244)
Noncontrolling interest	0	0
Total equity	(2,095)	(1,244)
Total liabilities and equity	$ 1,221	$ 1,477

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares outstanding	54,385,411	54,385,411

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
SUBLICENSE REVENUE	$ 0	$ 0
OPERATING EXPENSES:
Sublicense transaction costs	0	0
General and administrative	188	229
Research and development	601	301
Total operating expenses	789	530
Income (loss) after operating expenses	(789)	(530)
Interest and other income (expense), net	(63)	(60)
Income (loss) from operations before taxes	(852)	(590)
Income tax benefit (expense)	(3)	3
NET INCOME (LOSS)	(855)	(587)
Less: Net Income (Loss) attributable to the noncontrolling interest	0	0
Net Income (Loss) attributable to Capstone Therapeutics Corp. stockholders	$ (855)	$ (587)
Per Share Information:
Net Income (Loss), basic and diluted, attributable to Capstone Therapeutic Corp. stockholders	$ (0.02)	$ (0.01)
Basic and diluted shares outstanding	54,385	54,385

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
OPERATING ACTIVITIES
Net loss	$ (855)	$ (587)
Non cash items:
Amortization	39	39
Non-cash interest expense	59	59
Non-cash stock based interest expense	4	2
Change in other operating items:
Other current assets	(5)	10
Accounts payable	385	6
Other accrued liabilities	74	1
Cash flows used in operating activities	(299)	(470)
INVESTING ACTIVITIES
Cash flows provided by investing activities	0	0
FINANCING ACTIVITIES
Secured Debt funding	50	0
Cash flows provided by financing activities	50	0
NET DECREASE IN CASH	(249)	(470)
CASH, BEGINNING OF PERIOD	1,341	1,275
CASH, END OF PERIOD	$ 1,092	$ 805

XML 16 R6.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Business Description and Accounting Policies [Text Block]

Note A. OVERVIEW OF BUSINESS

Description of the Business

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Company History

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Basis of presentation, Going Concern, and Management’s Plans.

The accompanying financials statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

Use of estimates.

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires that management make a number of assumptions and estimates that affect the reported amounts of assets, liabilities, and expenses in our financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s assumptions regarding current events and actions that may impact the Company in the future, actual results may differ from these estimates and assumptions.

Our significant estimates include accounting for stock-based compensation.

Legal and Other Contingencies

The Company is subject to legal proceedings and claims, as well as potential inquires and action by the Securities and Exchange Commission, that arise in the course of business. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably estimated. In the opinion of management, there was not at least a reasonable possibility the Company may have incurred a material loss with respect to loss contingencies. However, the outcome of legal proceedings and claims brought against the Company are subject to significant uncertainty.

Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.

Joint Venture Accounting.

The Company entered into a joint venture in which it has contributed $6,000,000, and the noncontrolling interests have contributed certain patent license rights. As discussed in Note B below, in August 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000. Neither the Company nor the noncontrolling interests have an obligation to contribute additional funds to the joint venture or to assume any joint venture liabilities or to provide a guarantee of either joint venture performance or any joint venture liability. The financial position and results of operations of the joint venture are presented on a consolidated basis with the financial position and results of operations of the Company. Intercompany transactions have been eliminated. Joint venture losses were recorded on the basis of common ownership equity interests until common ownership equity was reduced to $0. Subsequent joint venture losses were allocated to the Series A preferred ownership. Subsequent to March 31, 2013, all joint venture losses had been allocated to the Company. On August 25, 2016, the JV raised $1,012,000 ($946,000 net of issuance costs) in a Series B-1 Preferred Stock and Warrant offering and in 2016, $946,000 in losses were allocated to the Series B-1 Preferred Stock ownership interests. As of March 31, 2018, losses incurred by the JV exceeded the capital accounts of the JV. The Company has a revolving loan agreement with the joint venture and advanced the joint venture funds for operations, with the net amount originally due December 31, 2016. As described in Note B below, the due date of the revolving loan has been extended to July 15, 2020, with early payment required upon certain additional funding of the joint venture by non-affiliated parties. Losses incurred by the joint venture in excess of the capital accounts of the joint venture will be allocated to the Company to the extent of net outstanding advances.

Cash.

Cash consists of balances held in commercial bank accounts.

Accounts Payable.

Accounts payable includes officer compensation of

158,000 and $135,000 at March 31, 2019 and December 31, 2018, respectively, that is payable the earlier of July 15, 2020, occurrence of certain transaction or approval by the Company’s Board of Directors. Accounts payable at March 31, 2019 also includes a $416,000 payable associated with the Cooperation Agreement discussed below.

Stockholders’ Equity.

During the 1

quarter of 2019 and 2018 Additional paid-in capital increased by $4,000 and $2,000, respectively, due to the amortization of the cost of Warrants issued as part of the First Amendment to Securities Purchase, Loan and Security Agreement as described in Note D in these Consolidated Financial Statements. During the 1

quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.

Revenue Recognition

Upfront License Fees

: If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the collaborator and the collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, the Company applies an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Recent Accounting Pronouncements

Leases.

In February 2016 the FASB issued ASU 2016-02

Leases (Topic 842)

and subsequently amended the guidance relating largely to transition considerations under the standard in January 2018 and July 2018. The objective of this update is to increase the transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The new standard was adopted by the Company in the 1

quarter of 2019 and the adoption did not have a material effect on its financial position or operating results. The Company, at March 31, 2019, has recorded a right to use asset of $28,000 in Other Current Assets and a lease liability of $28,000 in Other Accrued Liabilities in the Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. The adoption of the new standard is a non-monetary transaction and will have no effect on the Consolidated Statement of Cash Flows.

Cooperation Agreement.

In May 2018 the Company’s joint venture (“JV”) entered into an agreement to cooperate with Anji Pharmaceuticals Inc. (“ANJI”) (see Note E to the Financial Statements included in this Quarterly Report on Form 10-Q) in the development of AEM-28 and its analogs. The JV entered into a License Agreement (the “Sub-License”) with ANJI to sublicense, under its Exclusive License Agreement with the UAB Research Foundation, the use of the JV’s AEM-28 and analogs intellectual property in the Territory of the People’s Republic of China, Taiwan and Hong Kong (the “Territory”). As both parties intend to develop AEM-28 and its analogs, conducting independent development activities would result in both parties performing the same or similar pre-clinical work and clinical trial drug development. As such, the parties agreed to cooperate by the JV agreeing to perform certain preclinical work at its expense and for ANJI to cover the cost of clinical trial drug development. For efficiency and cost effectiveness the JV has agreed to manage the initial clinical trial drug development. Accordingly, the vendors performing the clinical trial drug development will bill the JV and ANJI will reimburse the JV. As provided for in ASC 606 and ASC 808 Cooperation Arrangements, the JV will net the reimbursements against the clinical trial drug development costs in Operating Expenses – Research & Development in the Consolidated Statements of Operations and the cash flow effect will be shown net in Operating Activities – Net Loss in the Consolidated Statements of Cash Flows in the Financial Statements included in this Current Report on Form 10-Q. ANJI cost and reimbursement activity under the Cooperation Agreement as of March 31, 2019 and December 31, 2018 totaled $114,000 and $52,000, respectively, and has been shown net. In the 1

quarter of 2019 the Company charged costs totaling $401,000 to research and development expense related to its activities under the Cooperation Agreement.

XML 17 R7.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

Note B. JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS

As disclosed above, on August 11, 2017, the Company purchased 93,458 shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock for $1,000,000.

quarter of 2019 a Management Fee of $50,000 was charged to expense and paid in the second quarter of 2019..

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667	)
Cash paid at formation	$	378

Patent license rights were recorded at their estimated fair value and were amortized on a straight-line basis over the key patent life of eighty months.

XML 18 R8.htm IDEA: XBRL DOCUMENT

AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT

3 Months Ended

Mar. 31, 2019

Research and Development Expense [Abstract]

Refundable Research And Development Credit [Text Block]

Note C

Australian Refundable Research & Development Credit

XML 19 R9.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

Issuance Of Common Stock And Secured Debt Disclosure [Text Block]

Note D

SALE OF COMMON STOCK AND ISSUANCE OFSECURED debT

quarter of 2019 and 2018, respectively, and is included in Interest and other expenses, net, in the Condensed Consolidated Statement of Operations.

quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses. At March 31, 2019 and December 31, 2018, unamortized transaction costs of $142,000 and $165,000, respectively, have been netted against the outstanding Secured Debt balance on the Condensed Consolidated Balance Sheets. Interest payable on the Secured Debt is now due at loan maturity, October 15, 2020, and, at March 31, 2019 and December 31, 2018, accrued interest of $249,000 and $213,000, respectively, has been included in the Secured Debt balance on the Condensed Consolidated Balance Sheets. The interest on the secured debt of $36,000 in 1

quarter of 2019 and 2018 has been included in the Condensed Consolidated Statements of Operations in Interest and Other Expenses.

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2019			December 31, 2018

Secured Debt	$	2,477		$	2,427
Transaction costs		(299	)		(299	)
	$	2,178		$	2,128
Amortization		157			134
	$	2,335		$	2,262
Accrued interest		249			213
	$	2,584		$	2,475

A provision in the Agreement entered into with Brookstone also requires the Company to nominate two candidates for a director position that have been recommended by Brookstone as long as Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.

XML 20 R10.htm IDEA: XBRL DOCUMENT

LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

3 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

Subsequent Events [Text Block]

Note E LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT

XML 21 R11.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Description Of Business [Policy Text Block]

Description of the Business

The JV and the Company are exploring fundraising, partnering or licensing, to obtain additional funding to continue development activities and operations.

Description of Current Peptide Drug Candidates.

Apo E Mimetic Peptide Molecule – AEM-28 and its analogs

Company History [Policy Text Block]

Company History

On August 3, 2012, we entered into a joint venture (As described in Note B below) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Basis Of Presentation and Management Plan [Policy Text Block]

Basis of presentation, Going Concern, and Management’s Plans.

93,458

shares of LipimetiX Development, Inc.’s Series B-2 Preferred Stock. The additional funds, as well as a commitment of additional funding from the same investor on an as needed basis of up to $500,000, (Through an increase in its outstanding long-term debt as described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2019, on March 15, 2019 the Company entered into the Second Amendment to Securities Purchase, Loan and Security Agreement with Brookstone which provides additional funding for our operations up to a Maximum Amount of $500,000) alleviated the substantial doubt about the entity’s ability to continue as a going concern. However, additional funds will be required for the joint venture to reach its development goals and for the Company to continue its planned operations.

Use of Estimates, Policy [Policy Text Block]

Use of estimates.

Our significant estimates include accounting for stock-based compensation.

Commitments and Contingencies, Policy [Policy Text Block]

Legal and Other Contingencies

Legal costs related to contingencies are expensed as incurred and were not material in either 2019 or 2018.

Interest in Unincorporated Joint Ventures or Partnerships, Policy [Policy Text Block]

Joint Venture Accounting.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash.

Cash consists of balances held in commercial bank accounts.

Accounts Payable Policy [Policy Text Block]

Accounts Payable.

Accounts payable includes officer compensation of

Stockholders' Equity, Policy [Policy Text Block]

Stockholders’ Equity.

During the 1

quarter of 2019 and 2018 Accumulated deficit increased by $855,000 and $587,000, respectively, due to the net loss incurred in those quarters.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Upfront License Fees

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Leases.

In February 2016 the FASB issued ASU 2016-02

Leases (Topic 842)

Cooperation Agreement.

52,000

, respectively, and has been shown net. In the 1

quarter of 2019 the Company charged costs totaling $

401,000

to research and development expense related to its activities under the Cooperation Agreement.

XML 22 R12.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables)

3 Months Ended

Mar. 31, 2019

Business Combinations [Abstract]

Schedule Of Joint Venture Payments [Table Text Block]

The joint venture formation was as follows ($000’s):

Patent license rights	$	1,045
Noncontrolling interests		(667	)
Cash paid at formation	$	378

XML 23 R13.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables)

3 Months Ended

Mar. 31, 2019

Stockholders' Equity Note [Abstract]

Schedule of Debt [Table Text Block]

A summary of the Secured Debt activity is as follows (000’s):

	March 31, 2019			December 31, 2018

Secured Debt	$	2,477		$	2,427
Transaction costs		(299	)		(299	)
	$	2,178		$	2,128
Amortization		157			134
	$	2,335		$	2,262
Accrued interest		249			213
	$	2,584		$	2,475

XML 24 R14.htm IDEA: XBRL DOCUMENT

OVERVIEW OF BUSINESS (Details Textual) - USD ($)			1 Months Ended		3 Months Ended		12 Months Ended
OVERVIEW OF BUSINESS (Details Textual) - USD ($)	Aug. 11, 2017	Jul. 14, 2017	Aug. 31, 2017	Aug. 25, 2016	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Aug. 03, 2012
Accounting Policies [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures					$ 6,000,000			$ 6,000,000
Line of Credit Facility, Maximum Borrowing Capacity					500,000
Proceeds from Issuance of Preferred Stock and Preference Stock					0
Accounts Payable					158,000		$ 135,000
Research and Development Expense					401,000
Reimbursement of revenue					$ 114,000		52,000
Equity Method Investment, Ownership Percentage					20.00%
Net Income (Loss) Attributable to Parent					$ (855,000)	$ (587,000)
Operating Lease, Right-of-Use Asset					28,000
Accounts Payable Corporation Agreement					416,000
Additional fund for operations					500,000
Other Assets [Member]
Accounting Policies [Line Items]
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability					28,000
Series B-1 Preferred Stock [Member]
Accounting Policies [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock				$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs				1,012,000
Payments of Stock Issuance Costs				66,000
Joint Venture Losses Recognition Criteria Common Ownership Equity				946,000
Series B2 Preferred Stock [Member]
Accounting Policies [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock					$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs				1,012,000
Stock Issued During Period, Value, Acquisitions	$ 1,000,000		$ 1,000,000	$ 1,000,000
Stock Issued During Period, Shares, Acquisitions	93,458		93,458	93,458
Payments of Stock Issuance Costs		$ 287,000
Joint Venture Losses Recognition Criteria Common Ownership Equity				$ 946,000
Brookstone [Member]
Accounting Policies [Line Items]
Proceeds from Related Party Debt		3,440,000
Proceeds From Related Party Debt, Net		$ 2,074,000
Lipimetix [Member]
Accounting Policies [Line Items]
Equity Method Investment, Ownership Percentage					60.00%
Common Stock [Member]
Accounting Policies [Line Items]
Joint Venture Losses Recognition Criteria Common Ownership Equity					$ 0
Additional Paid-in Capital [Member]
Accounting Policies [Line Items]
Amortisation Of Financing Cost Of Warrants					4,000	$ 2,000
Retained Earnings [Member]
Accounting Policies [Line Items]
Net Income (Loss) Attributable to Parent					$ 855,000		$ 587,000

XML 25 R15.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) - Lipimetix [Member] - USD ($)		3 Months Ended
	Aug. 03, 2012	Mar. 31, 2019
Related Party Transaction [Line Items]
Patent license rights		$ 1,045,000
Noncontrolling interests		(667,000)
Cash paid at formation	$ 378,000	$ 378,000

XML 26 R16.htm IDEA: XBRL DOCUMENT

JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)				1 Months Ended				3 Months Ended		12 Months Ended	77 Months Ended
	Aug. 11, 2017	Jul. 14, 2017	Aug. 03, 2012	Oct. 27, 2017	Aug. 31, 2017	Aug. 25, 2016	Mar. 31, 2016	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 6,000,000					$ 6,000,000
Joint Venture Investments In Voting Common Ownership Units (in shares)			600,000
Joint Venture Investments In Non Voting Preferred Ownership Units			5,000,000
Joint Venture, Operating Expenses, Inter Company Transactions								684,000			$ 10,282,000
Joint Venture, Operating Expenses Allocated To Company											8,670,000
Percentage Of Non Royalty Income	5.00%		5.00%
Conversion of Stock, Shares Converted	(3,500,000)
Conversion of Stock, Shares Issued							120,000
Joint Venture Method Investment Ownership Percentage			60.00%
Proceeds from Issuance of Preferred Stock and Preference Stock								0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						33,088
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 10.70
Management Fees								50,000
Operating Expenses Net Of Elimination Of Intercompany Transactions								684,000
Conversion of Stock, Amount Converted	$ 3,500,000
Conversion of Stock, Amount Issued	$ 1,000,000
Interest Payable								$ 249,000		$ 213,000	$ 213,000
Accrued Professional Fees					$ 20,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant										83,480	83,480
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				14,126
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 10.70
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage										50.00%
Ownership As Converted [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage										65.11%
Ownership As Converted Including Options And Warrants [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage				64.31%
Joint Venture [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent								100.00%
Series B1 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity						$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs						1,012,000
Proceeds from Issuance of Preferred Stock and Preference Stock						946,000
Payments of Stock Issuance Costs						$ 66,000
Stock Issued During Period, Shares, New Issues						94,537
Management Fees					$ 300,000
Management Fee Expense								$ 150,000	$ 150,000
Accrued Professional Fees								400,000
Series B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Losses Recognition Criteria, Common Ownership Equity						$ 946,000
Proceeds From Issuance Of Preferred Stock Before Adjusted Stock Issuance Costs						$ 1,012,000
Proceeds from Issuance of Preferred Stock and Preference Stock								946,000
Payments of Stock Issuance Costs		$ 287,000
Stock Issued During Period, Shares, Acquisitions	93,458				93,458	93,458
Stock Issued During Period, Value, Acquisitions	$ 1,000,000				$ 1,000,000	$ 1,000,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 15,000
Series B1 And B2 Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage			62.20%
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage			69.75%
Revolving Credit Facility [Member]
Related Party Transaction [Line Items]
Long-term Line of Credit								1,740,000
Interest Payable								140,000
Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of Stock, Shares Converted							1,500,000
Noncontrolling Interest [Member]
Related Party Transaction [Line Items]
Noncash or Part Noncash Acquisition, Other Liabilities Assumed											$ 667,000
Maximum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage							64.00%
Minimum [Member]
Related Party Transaction [Line Items]
Joint Venture Method Investment Ownership Percentage							60.00%
Exclusive License Agreement [Member]
Related Party Transaction [Line Items]
Percentage Of Royalty Payment						3.00%
Annual Maintenance Payments						$ 25,000
Exclusive License Agreement [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Milestone Payments						500,000
Royalty Expense			$ 1,000,000
Exclusive License Agreement [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Milestone Payments						$ 50,000
Royalty Expense			$ 500,000
Lipimetix [Member]
Related Party Transaction [Line Items]
Joint Venture Investments Common Ownership Units, Co-venture (in shares)			400,000
Ownership Percentage Co-venture			40.00%
Noncash or Part Noncash Acquisition, Other Liabilities Assumed								667,000
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)			$ 378,000					$ 378,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										81,479
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 1.07
Voting Common Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			1,000,000
Non Voting Preferred Ownership Units [Member]
Related Party Transaction [Line Items]
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures			$ 5,000,000

XML 27 R17.htm IDEA: XBRL DOCUMENT

AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Research And Development Disclosure [Line Items]
Research and Development Expense		$ 401,000
Tax Credit Carryforward, Amount				$ 4,000
Lipimetix Australia Pty Ltd [Member]
Research And Development Disclosure [Line Items]
Research and Development Expense		$ 0	$ 4,000
Lipimetix Australia Pty Ltd [Member] \| Minimum [Member]
Research And Development Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent	43.50%

XML 28 R18.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Secured Debt	$ 2,477	$ 2,427
Transaction costs	(299)	(299)
Long-term Debt, Gross	2,178	2,128
Amortization	157	134
Secured Long term Debt Gross	2,335	2,262
Accrued interest	249	213
Secured Long-term Debt, Noncurrent	$ 2,584	$ 2,475

XML 29 R19.htm IDEA: XBRL DOCUMENT

SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) - USD ($)					1 Months Ended			3 Months Ended
	Mar. 15, 2019	Aug. 11, 2017	Jul. 14, 2017	Dec. 11, 2015	Aug. 31, 2017	Apr. 18, 2017	Aug. 25, 2016	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Debt Instrument, Maturity Date				Apr. 30, 2017
Interest Payable								$ 249,000		$ 213,000
Secured Long-term Debt, Noncurrent								2,584,000		2,475,000
Debt Instrument, Increase (Decrease), Net	$ 700,000
Amortization								39,000	$ 39,000
Common Stock, Value, Issued								27,000		27,000
Additional fund for operations								$ 500,000
Equity Method Investment, Ownership Percentage								20.00%
Derivative, Fixed Interest Rate								6.00%
Warrants and Rights Outstanding, Maturity Date								Oct. 15, 2025
Convertible Notes Payable [Member]
Interest Payable			$ 79,000
Convertible Notes Payable, Noncurrent			1,000,000
Brookstone [Member]
Proceeds from Related Party Debt			3,440,000
Proceeds From Related Party Debt, Net			2,074,000
Stock Repurchased During Period, Value			$ 1,012,500
Stock Repurchased During Period, Shares			13,500,000
Secured Long-term Debt, Noncurrent			$ 2,427,500
Amortization of Debt Issuance Costs								$ 157,000	23,000
Unamortized Debt Issuance Expense								$ 142,000		165,000
Equity Method Investment, Description of Principal Activities			Brookstone beneficially owns over 20% of the Company’s outstanding common stock and to nominate one candidate for a director position that has been recommended by Brookstone as long as Brookstone beneficially owns over 5% but less than 20% of the Company’s outstanding common stock.
Stock Issued During Period, Shares, New Issues			5,041,197			5,041,197		18,541,197
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners								34.10%
Debt Issuance Costs, Net								$ 287,000
Payment of Financing and Stock Issuance Costs								$ 12,000
Class of Warrant or Right, Outstanding								6,321,930
Amortization								$ 4,000	2,000
Warrants and Rights Outstanding								43,000
Common Stock, Value, Issued								0.75
Additional fund for operations	500,000							$ 50,000
Brookstone [Member] \| Convertible Notes Payable [Member]
Class of Warrant or Right, Outstanding								2,926,302
Common Stock, Value, Issued								$ 0.75
Brookstone [Member] \| Minimum [Member]
Beneficial Ownership Percentage						4.99%
Equity Method Investment, Ownership Percentage								5.00%
Interest and Other Expenses [Member]
Interest Expense, Debt								$ 36,000	$ 36,000
Secured Debt [Member]
Interest Payable								$ 249,000		$ 213,000
Secured Debt, Current	$ 500,000
Series B2 Preferred Stock [Member]
Stock Issued During Period, Shares, Acquisitions		93,458			93,458		93,458
Stock Issued During Period, Value, Acquisitions		$ 1,000,000			$ 1,000,000		$ 1,000,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018
Revenues	$ 0	$ 2,000,000	$ 0
Sublicense Transaction Costs	0		$ 0
Royalty [Member]
Revenue from Contract with Customer, Including Assessed Tax	2,000,000
License [Member]
Revenues	2,000,000
Sublicense Transaction Costs	254,000
UAB Research Foundation Expense	100,000
Advisory Fees	100,000
Legal Fees	$ 54,000

EXCEL 31 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 32 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 33 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 81 157 1 false 28 0 false 4 false false R1.htm 1001 - Document - Document and Entity Information Sheet http://www.capstonethx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.capstonethx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 1004 - Statement - CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementOfOperations CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS Statements 4 false false R5.htm 1005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.capstonethx.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 1006 - Disclosure - OVERVIEW OF BUSINESS Sheet http://www.capstonethx.com/role/OverviewOfBusiness OVERVIEW OF BUSINESS Notes 6 false false R7.htm 1007 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS Notes 7 false false R8.htm 1008 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT Notes 8 false false R9.htm 1009 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT Notes 9 false false R10.htm 1010 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT Sheet http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT Notes 10 false false R11.htm 1011 - Disclosure - OVERVIEW OF BUSINESS (Policies) Sheet http://www.capstonethx.com/role/OverviewOfBusinessPolicies OVERVIEW OF BUSINESS (Policies) Policies 11 false false R12.htm 1012 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Tables) Tables http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogs 12 false false R13.htm 1013 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Tables) Tables http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebt 13 false false R14.htm 1014 - Disclosure - OVERVIEW OF BUSINESS (Details Textual) Sheet http://www.capstonethx.com/role/OverviewOfBusinessDetailsTextual OVERVIEW OF BUSINESS (Details Textual) Details http://www.capstonethx.com/role/OverviewOfBusinessPolicies 14 false false R15.htm 1015 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetails JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 15 false false R16.htm 1016 - Disclosure - JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Sheet http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsDetailsTextual JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) Details http://www.capstonethx.com/role/JointVentureForDevelopmentOfApoEMimeticPeptideMoleculeAem28AndAnalogsTables 16 false false R17.htm 1017 - Disclosure - AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) Sheet http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCreditDetailsTextual AUSTRALIAN REFUNDABLE RESEARCH & DEVELOPMENT CREDIT (Details Textual) Details http://www.capstonethx.com/role/AustralianRefundableResearchDevelopmentCredit 17 false false R18.htm 1018 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetails SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details) Details http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables 18 false false R19.htm 1019 - Disclosure - SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) Sheet http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtDetailsTextual SALE OF COMMON STOCK AND ISSUANCE OFSECURED DEBT (Details Textual) Details http://www.capstonethx.com/role/SaleOfCommonStockAndIssuanceOfsecuredDebtTables 19 false false R20.htm 1020 - Disclosure - LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) Sheet http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreementDetailsTextual LIPIMETIX DEVELOPMENT, INC. LICENSE AGREEMENT (Details Textual) Details http://www.capstonethx.com/role/LipimetixDevelopmentIncLicenseAgreement 20 false false All Reports Book All Reports caps-20190331.xml caps-20190331.xsd caps-20190331_cal.xml caps-20190331_def.xml caps-20190331_lab.xml caps-20190331_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 36 0001171843-19-003295-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-19-003295-xbrl.zip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�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end

	March 31,			December 31,
	2019			2018
	(Unaudited)
ASSETS
Current assets
Cash	$	1,092		$	1,341
Other current assets		129			97
Total current assets		1,221			1,438

Patent license rights, net		-			39
Total assets	$	1,221		$	1,477

LIABILITIES AND EQUITY
Current liabilities
Accounts payable	$	630		$	245
Other accrued liabilities		102			1
Total current liabilities		732			246

Secured debt and accrued interest, net of unamortized issuance costs		2,584			2,475

Equity
Capstone Therapeutics Corp. Stockholders' Equity
Common Stock$.0005 par value; 150,000,000 shares authorized; 54,385,411 shares outstanding in 2019 and 2018		27			27
Additional paid-in capital		190,487			190,483
Accumulated deficit		(192,609	)		(191,754	)
Total Capstone Therapeutics Corp. stockholders' equity (deficit)		(2,095	)		(1,244	)
Noncontrolling interest		-			-
Total equity		(2,095	)		(1,244	)
Total liabilities and equity	$	1,221		$	1,477